Erythromycin
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Erythromycin | 250-500mg PO Q12H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 734 | 15 | 1.4 | 5-6 | 60-95 | 0.6-1.2 | 28.5 | 0.02-20 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00199
- Iliopoulou A, Downey K, Chaput de Saintonge D, Turner P. Should erythromycin dose be altered in haemodialysis patients? European journal of clinical pharmacology 1982; 23(5), 435-40.
- Kroboth P, McNeil M, Kreeger A, Dominguez J, Rault, R. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Archives of internal medicine 1983; 143(6), 1263-5.
- Mery J, Kanfer A. Hearing Loss and Erythromycin Pharmacokinetics in Patients Receiving Hemodialysis. Archives of internal medicine 1984; 144, 419-20.
- Vaziri N, Cesario T, Valentic, J, Saiki J, Tilles J. Hemodialysis of Erythromycin. Drug Intelligence & Clinical Pharmacy 1980;4, 549-551.